Kepravin Dry Cow 250mg Intramammary Suspension

Main information

  • Trade name:
  • Kepravin Dry Cow 250mg Intramammary Suspension
  • Pharmaceutical form:
  • Intramammary suspension
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Kepravin Dry Cow 250mg Intramammary Suspension
    Malta
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • cefalonium
  • Therapeutic area:
  • Cattle Lactating

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0343/001
  • Authorization date:
  • 25-07-2012
  • EU code:
  • UK/V/0343/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:September2012

AN:00840/2011

Page1of7

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

UK:KepravineDryCow250mgIntramammarySuspension

AT,CY,DE,EE,LT,LV,MT,NL:CepravinDryCow250mgIntramammarySuspension

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachintramammarysyringewith3gsuspensioncontains:

Activesubstance:

Cefalonium(ascefaloniumdihydrate) 0.25g

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Intramammarysuspension.

Whitetocreamcolouredsuspension.

4. CLINICALPARTICULARS

4.1Targetspecies

Dairycattle(cowsatdryingoff).

4.2Indicationsforuse,specifyingthetargetspecies

Forthetreatmentofsubclinicalmastitisatdrying-offandthepreventionofnewbacterial

infectionsoftheuddercausedbyStaphylococcusaureus,Streptococcusagalactiae,

Streptococcusdysgalactiae,Streptococcusuberis,Arcanobacteriumpyogenes,

EscherichiacoliandKlebsiellaspp.duringthenon-lactatingperiodofcows.

4.3Contraindications

Nottobeadministeredtoanimalswhichareknowntobehypersensitiveto

cephalosporinantibioticsandotherβ-lactamantibiotics.

Pleaserefertosection4.7

Issued:September2012

AN:00840/2011

Page2of7

4.4Specialwarnings

None.

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Donotbendthenozzle.

Donotcontaminatethenozzle.

Useoftheproductshouldbebasedonsusceptibilitytestingandshouldtakeinto

accountofficialandlocalantimicrobialpolicies.Increaseduse,includinguseofthe

productdeviatingfromtheinstructionsgivenintheSPC,mayincreasetheprevalenceof

bacteriaresistanttocefalonium.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Washhandsafteruse.

Penicillinandcephalosporinsmaycausesensitisation(allergy)followinginjection,

inhalation,ingestionorskincontact.Sensitivitytopenicillinmayleadtocross-sensitivity

tocephalosporinandviceversa.Allergicreactionstothesesubstancesmay

occasionallybeserious.

Donothandlethisproductifyouknowyouaresensitised,orifyouhavebeenadvised

nottoworkwithsuchpreparations.

Handlethisproductwithgreatcaretoavoidexposure,takingallrecommended

precautions.

Ifyoudevelopsymptomsfollowingexposuresuchasaskinrashyoushouldseek

medicaladviceandshowtheDoctorthiswarning.Swellingoftheface,lipsoreyesor

breathingdifficultiesaremoreserioussymptomsandrequireurgentmedicalattention.

4..6Adversereactions(frequencyandseriousness)

Noneknown

Issued:September2012

AN:00840/2011

Page3of7

4.7Useduringpregnancy,lactationorlay

Intendedforuseduringthelasttrimesterofpregnancyoncethelactatingcowhasbeen

driedoff.Thereisnoadversetreatmenteffectonthefoetus.

Nottobeusedinlactatingcows.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

4.9Amountstobeadministeredandadministrationroute

Forintramammaryuse.

Thecontentofonesyringeshouldbeinfusedintotheteatcanalofeachquarter

immediatelyafterthelastmilkingofthelactation.Beforeinfusion,theteatshouldbe

thoroughlycleanedanddisinfectedwiththecleaningtowelprovided.Avoid

contaminationofthenozzleafterremovingthecap.

Option1:Forshortnozzleintramammaryadministration:holdthebarrelofthe

syringeandthebaseofthecapinonehandandtwistoffthesmallupperpartofthecap

abovetheindentmark(thebaseportionofthecapremainsonthesyringe).Takecare

nottocontaminatetheshortexposedpartofthenozzle.

Option2:Forfullnozzleintramammaryadministration:removethecapfullyby

holdingthebarrelofthesyringefirmlyinonehandandwiththethumbpushupandalong

thelengthofthecapuntilthecapclicksoff.Takecarenottocontaminatethenozzle.

Insertthenozzleintotheteatcanalandapplysteadypressureonthesyringeplunger

untilthefulldosehasbeendelivered.Holdingtheendoftheteatwithonehand,gently

massageupwardswiththeothertoaiddispersionoftheantibioticintothequarter.

Finallyimmersetheteatsinateatdip.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Repeateddosesincattleonthreeconsecutivedaysdidnotdemonstrateorproduceany

adverseeffects.

Issued:September2012

AN:00840/2011

Page4of7

4.11Withdrawalperiod(s)

Meatandoffal:

21days

Milk:

oIntervaltreatment- calving≥54days:withdrawalperiod=96hoursaftercalving.

oIntervaltreatment-calving<54days:withdrawalperiod=54daysplus96hours

aftertreatment,ensuringthatatleast7completemilkingsarediscarded.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Cephalosporinsandrelatedsubstances

ATCvetcode:QJ51DB90

5.1Pharmacodynamicproperties

Theproductisalong-actingintramammarysuspensioncontainingcefaloniumdihydrate,

asemi-syntheticcephalosporinantibiotic.Itisformulatedtogivepersistentantibiotic

levelsinthedryudder.

Cefaloniumisanantibacterialdrugofthecephalosporingroupwhichactsbyinhibition

ofcellwallsynthesis(bactericidalmodeofaction).Itischaracterisedbyitsbroad

therapeuticspectrumofactivityandahighstabilityagainstbeta-lactamases.

Cefaloniumisactiveagainst:Corynebacteriumbovis,Staphylococcusaureus,

Streptococcusagalactiae,Streptococcusdysgalactiae,Streptococcusuberis,

Escherichiacoli,Klebsiellaspp.andArcanobacteriumpyogenes.

MICdatawasgeneratedforGram-positiveandGram-negativeisolatesovertheperiod

2000to2006.Particularregardwaspaidtothefollowingmastitispathogens:

Staphylococcusaureus,Streptococcusagalactiae,Streptococcusdysgalactiae,

Streptococcusuberis,Escherichiacoli,Klebsiellaspp.andArcanobacterium

pyogenes.AnoverviewoftheMIC

90 values

ofthesebacterialmastitispathogensis

presentedinthetablebelow:

Issued:September2012

AN:00840/2011

Page5of7

Table1:Summaryofsusceptibilitydataforcefaloniumagainstmastitisisolatesfrom

theperiod2000to2006

Organism YearofIsolation n MICrange

(µg/mL) MIC

90

(µg/mL)

Staphylococcus

aureus 2000 –2006 120 ≤0.03–0.125 0.125

Streptococcus

agalactiae 2004-2005 11 0.0078 –0.0156 0.0156

Streptococcus

dysgalactiae 2000-2006 123 0.00375 –0.06 0.0078

Streptococcus

uberis 2000-2005 1200.00375 –0.125 0.06

Arcanobacteriu

mpyogenes 2000-2006 38 0.03 –0.125 0.125

Escherichiacoli 2000 –2006

64 0.5 –4

2

Klebsiellaspp. 2000 –2006

64 1-4 2

.CattletreatedwithCepravinDryCowhavelowersomaticcellcountsaftercalving.

5.2Pharmacokineticparticulars

Pharmacokineticsofcefaloniuminthetargetspecieshasbeeninvestigatedfollowing

intramammaryadministrationinseveralstudies.Thepresenceofcefaloniumand/orits

biologicallyactivemetaboliteswasdetectedinurineandserum.

Cefaloniumisextensivelybutslowlyabsorbedfromtheudderandexcretedprimarilyin

theurine.Between7and13%oftheactivesubstanceiseliminatedinurineoneachof

thefirstthreedayspostdosingwhilstdailyexcretioninfaecesis<1%overthesame

period.

Meanbloodconcentrationremainsfairlyconstantduringapproximately10daysafter

dosingwhichisconsistentwithslowbutprolongedabsorptionofcefaloniumfromthe

udder.

Thelongtermpersistenceofcefaloniuminthedryudderwasexaminedoveratime

spanof10weeksafterinfusion.Efficientlevelsofcefaloniuminuddersecretaremained

upto10weeksafterinfusion.

6. PHARMACEUTICALPARTICULARS

Issued:September2012

AN:00840/2011

Page6of7

6.1Listofexcipients

Aluminiumdistearate

Liquidparaffin

6.2Incompatibilities

Notapplicable.

6.3Shelflife

Shelflifeoftheveterinarymedicalproductaspackagedforsale:3years

6.4.Specialprecautionsforstorage

Donotstoreabove30

C

Donotfreeze

6.5Natureandcompositionofimmediatepackaging

Singledose3gwhitepolyethylenesyringeswitharedpolyethylenedualpush-fitcap.

Boxesof20intramammarysyringeswithcleaningtowels.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

IntervetUKLimited

WaltonManor

Walton

MiltonKeynes

Buckinghamshire

MK77AJ

8. MARKETINGAUTHORISATIONNUMBER

Issued:September2012

AN:00840/2011

Page7of7

Vm01708/4587

9. DATEOFFIRSTAUTHORISATION

24September2012

10 DATEOFREVISIONOFTHETEXT

September2012

7-12-2018

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Published on: Thu, 06 Dec 2018 The present scientific opinion deals with the assessment of the bioavailability of magnesium, from the proposed nutrient source, magnesium citrate malate (MgCM), when added for nutritional purposes to food supplements. MgCM is a mixed salt consisting of magnesium cations and citrate and malate anions, and with a magnesium content of 12–15%. MgCM is proposed to be used in food supplements that are intended to provide up to 300–540 mg/day magnesium. The data provided demonst...

Europe - EFSA - European Food Safety Authority Publications

3-8-2018

Scientific guideline:  Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

31-7-2018

Public Notification: Black Rhino 25000 contains hidden drug ingredient

Public Notification: Black Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Black Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Krazzy Rhino 25000 contains hidden drug ingredient

Public Notification: Krazzy Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Krazzy Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Gold Rhino 25000 contains hidden drug ingredient

Public Notification: Gold Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Gold Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Platinum Rhino 25000 contains hidden drug ingredient

Public Notification: Platinum Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Platinum Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

10-7-2018

Preventieve HIV-remmers (PrEP) worden verstrekt voor een periode van vijf jaar

Preventieve HIV-remmers (PrEP) worden verstrekt voor een periode van vijf jaar

PrEP wordt binnen een onderzoekssetting voor een periode van vijf jaar verstrekt aan de hoogrisicogroep van mannen die seks hebben met mannen (MSM). Dat heeft minister Bruno Bruins (Medische Zorg) vandaag bekend gemaakt. Op basis van schattingen van het RIVM zullen ongeveer 6500 mannen hiervan gebruik gaan maken en kunnen hiermee  250 hiv-infecties per jaar worden voorkomen. Voor gebruikers gaat een eigen bijdrage gelden van maximaal 25%, dat komt overeen met ongeveer 12 euro per maand. Ook wordt hen gev...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

4-5-2018

Badger Botanicals Recalls Red Suma, Green Suma, Green Hulu 2, And Red Hulu 2 Kratom Supplements Because Of Possible Salmonella Health Risk

Badger Botanicals Recalls Red Suma, Green Suma, Green Hulu 2, And Red Hulu 2 Kratom Supplements Because Of Possible Salmonella Health Risk

Badger Botanicals, LLC of Springville, Utah is recalling Green Suma, Red Suma, Green Hulu 2, and Red Hulu 2 kratom dietary supplements sold directly to consumers via the company website from January 1st, 2018 to April l 12th, 2018 in pouches of 250g, because it has the potential to be contaminated with Salmonella.

FDA - U.S. Food and Drug Administration

20-7-2016

Marketing authorisation for medicine for cows suspended in the EU/EEA

Marketing authorisation for medicine for cows suspended in the EU/EEA

On 14 July 2016, the Committee for Medicinal Products for Veterinary Use (CVMP) recommended that the marketing authorisation for the centrally authorised medicinal product Velactis (cabergoline) be suspended temporarily. Velactis is used to reduce milk production in dairy cows at the time of drying off. The recommendation follows reports of serious adverse events after treatment with Velactis.

Danish Medicines Agency

21-6-2016

Use of medicine for cows suspended

Use of medicine for cows suspended

Today, the Danish Medicines Agency has decided to suspend the use of the veterinary medicine Velactis, which is used to reduce milk production (drying-off) in dairy cows.

Danish Medicines Agency

15-1-2014

Revocation of wholesale distribution and manufacturing authorisations granted to Singad Pharma ApS

Revocation of wholesale distribution and manufacturing authorisations granted to Singad Pharma ApS

On 20 December 2013 and on 10 January 2014, the Danish Health and Medicines Authority decided to revoke the section 39 authorisations for wholesale distribution and manufacturing of medicinal products with the authorisation IDs 25081 and 25082 granted to Singad Pharma ApS (company number 255894).

Danish Medicines Agency

30-10-2018

EU/3/14/1250 (Akcea Therapeutics UK Ltd)

EU/3/14/1250 (Akcea Therapeutics UK Ltd)

EU/3/14/1250 (Active substance: Phosphorothioate oligonucleotide targeted to transthyretin) - Transfer of orphan designation - Commission Decision (2018)7282 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/098/13/T/01

Europe -DG Health and Food Safety

6-6-2018

Stocrin (Merck Sharp and Dohme B.V.)

Stocrin (Merck Sharp and Dohme B.V.)

Stocrin (Active substance: efavirenz) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3689 of Wed, 06 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/250/T/113

Europe -DG Health and Food Safety